Reuters logo
FDA grants priority review to Roche's Lucentis for mCNV
October 11, 2016 / 5:42 AM / a year ago

FDA grants priority review to Roche's Lucentis for mCNV

ZURICH, Oct 11 (Reuters) - The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.

The ailment is a complication of severe near-sightedness that can lead to blindness, it added in a statement. (Reporting by Michael Shields, editing by John Revill)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below